Skip to main content

Advertisement

Table 1 Patient demographics and lung function at screening/baseline (intent-to-treat population)

From: Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial

  Placebo OD PM (N = 111) FF 50 mcg OD PM (N = 111)
Age, mean (SD) 33.8 (13.90) 36.7 (16.16)
Age range, years 12–68 12–77
Female, n (%) 70 (63) 63 (57)
Race, n (%)
  American Indian or Alaska Native 59 (53) 45 (41)
  White 29 (26) 42 (38)
  American Indian or Alaska Native and White 21 (19) 24 (22)
  Other 2 (2) 0
Screening characteristics, mean (SD)
Pre-bronchodilator FEV1 (L) 2.527 (0.6940) 2.452 (0.6843)
Percent predicted FEV1, % 77.33 (12.884) 74.71 (9.493)
Post-bronchodilator FEV1 (L) 3.139 (0.8784) 3.047 (0.8443)
Percent reversibility FEV1, % 24.32 (10.368) 24.77 (9.906)
Baseline characteristics, mean (SD)
Pre-bronchodilator FEV1* (L) 2.712 (0.8305) 2.669 (0.8172)
Percent predicted FEV1*, % 82.30 (14.115) 80.85 (12.277)
Rescue-free 24-h periods, % 7.5 (21.04) 10.2 (21.49)
Symptom-free 24-h periods, % 3.2 (12.73) 5.0 (14.53)
PM PEF (L/min) 356.8 (120.53) 359.0 (121.14)
AM PEF (L/min) 350.3 (115.89) 349.2 (117.21)
  1. *Assessed in 110 patients from each treatment arm; FEV1 = forced expiratory volume in one second; FF = fluticasone furoate; OD = once daily; PEF = peak expiratory flow PM = evening; SD = standard deviation.